Welcome to our dedicated page for Urogen Pharma SEC filings (Ticker: URGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UroGen Pharma Ltd.'s SEC filings document operating results, product revenue disclosures, financing agreements and governance matters for a biotechnology company focused on urothelial and specialty cancers. Recent 8-K reports furnish quarterly and annual financial results tied to JELMYTO and ZUSDURI, commercial launch updates, research and development expenses, reimbursement matters and pipeline disclosures involving UGN-103 and UGN-501.
Other filings describe material definitive agreements, including term-loan refinancing and credit arrangements with BioPharma Credit entities, as well as capital-structure information for ordinary shares listed on Nasdaq. Definitive proxy statements cover board matters, executive compensation, equity awards, pay-versus-performance tables and shareholder voting matters.
UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg reported equity compensation activity involving restricted stock units (RSUs) and ordinary shares. On January 31, 2026, previously granted RSUs converted into a total of 13,333 ordinary shares at an exercise price of $0, increasing his directly held ordinary shares.
On the same date, he received a new grant of 20,000 RSUs at $0. One-third of the shares underlying this new RSU award will vest on each of January 31, 2027, January 31, 2028, and January 31, 2029, providing staged future share delivery if vesting conditions are met.
UroGen Pharma Ltd. reported that its Chief Financial Officer, Chris Degnan, received a grant of restricted stock units on January 31, 2026. The award covers 32,609 RSUs, each representing a contingent right to receive one ordinary share of UroGen Pharma.
According to the grant terms, one-third of the shares underlying the RSUs will vest on each of January 31, 2027, January 31, 2028, and January 31, 2029, subject to the standard conditions. Following this grant, Degnan beneficially owns 32,609 derivative securities directly.
Mark Schoenberg filed a notice of proposed sale of restricted securities under Rule 144. The filing covers 13333 ordinary shares to be sold through Oppenheimer & Co. Inc., with an aggregate market value of 261460.13, on or about 02/02/2026 on the Nasdaq exchange.
The shares were acquired through restricted stock unit (RSU) grants from the issuer between 2023 and 2025. The notice also reports a prior sale of 10000 ordinary shares on 11/19/2025 for gross proceeds of 250005.00. By signing, the seller represents having no undisclosed material adverse information about the issuer.
UroGen Pharma Ltd. (URGN) reported an insider stock sale by its Chief Medical Officer. On 11/19/2025, the officer sold 10,000 ordinary shares in an open market transaction coded as a sale. The weighted average sale price was $25.00, with individual trades occurring between $25.00 and $25.02 per share.
The transaction was made under a pre-arranged Rule 10b5-1(c) trading plan that was adopted on 08/15/2025. After this sale, the officer directly beneficially owned 139,025 ordinary shares of UroGen Pharma.
UroGen Pharma Ltd. filed a Form S-8 to register additional ordinary shares for issuance under its 2017 Equity Incentive Plan. The filing uses General Instruction E to incorporate by reference prior effective S-8 registrations for the same plan. Exhibits include the Israeli legal opinion on share validity, auditor consent, plan documents, and the filing fee table.
UroGen Pharma Ltd. filed a Form S-8 to register additional ordinary shares for issuance under its 2017 Equity Incentive Plan. The filing uses General Instruction E to incorporate by reference prior effective S-8 registrations for the same plan. Exhibits include the Israeli legal opinion on share validity, auditor consent, plan documents, and the filing fee table.
UroGen Pharma (URGN) reported Q3 2025 results with revenue of $27,482 thousand, up from $25,204 thousand a year ago, as Jelmyto sales remained the primary driver and newly approved Zusduri contributed initial sales. Gross profit was $24,204 thousand. Operating expenses rose, led by selling, general and administrative costs of $37,582 thousand and research and development of $14,008 thousand, resulting in an operating loss of $27,386 thousand.
Net loss was $33,347 thousand (basic and diluted loss per share of $0.69). For the nine months, revenue reached $71,951 thousand with a net loss of $127,130 thousand. Cash, cash equivalents and marketable securities totaled $127.4 million as of September 30, 2025. The balance sheet reflected a prepaid forward obligation of $126,067 thousand and long‑term debt of $122,111 thousand. Shareholders’ deficit was $115,408 thousand.
Zusduri received FDA approval on June 12, 2025 and generated $1,779 thousand in Q3 sales, while Jelmyto delivered $25,703 thousand. Management stated that available cash and securities are expected to fund operations beyond one year from issuance. The company revised Q3 2024 loss per share to include 3,679,400 pre‑funded warrants in the weighted average shares outstanding.
UroGen Pharma (URGN) reported Q3 2025 results with revenue of $27,482 thousand, up from $25,204 thousand a year ago, as Jelmyto sales remained the primary driver and newly approved Zusduri contributed initial sales. Gross profit was $24,204 thousand. Operating expenses rose, led by selling, general and administrative costs of $37,582 thousand and research and development of $14,008 thousand, resulting in an operating loss of $27,386 thousand.
Net loss was $33,347 thousand (basic and diluted loss per share of $0.69). For the nine months, revenue reached $71,951 thousand with a net loss of $127,130 thousand. Cash, cash equivalents and marketable securities totaled $127.4 million as of September 30, 2025. The balance sheet reflected a prepaid forward obligation of $126,067 thousand and long‑term debt of $122,111 thousand. Shareholders’ deficit was $115,408 thousand.
Zusduri received FDA approval on June 12, 2025 and generated $1,779 thousand in Q3 sales, while Jelmyto delivered $25,703 thousand. Management stated that available cash and securities are expected to fund operations beyond one year from issuance. The company revised Q3 2024 loss per share to include 3,679,400 pre‑funded warrants in the weighted average shares outstanding.
UroGen Pharma (URGN) reported that it announced financial results for the quarter ended September 30, 2025. The details are provided in a press release furnished as Exhibit 99.1.
The information was furnished under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act or incorporated by reference unless specifically stated. UroGen’s ordinary shares trade on Nasdaq under the symbol URGN.
UroGen Pharma (URGN) reported that it announced financial results for the quarter ended September 30, 2025. The details are provided in a press release furnished as Exhibit 99.1.
The information was furnished under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act or incorporated by reference unless specifically stated. UroGen’s ordinary shares trade on Nasdaq under the symbol URGN.
Chris Degnan, Chief Financial Officer of UroGen Pharma Ltd. (URGN), reported equity changes related to restricted stock units. The reporting notes a grant of 13,450 RSUs on 10/08/2024 that vest in three equal annual installments beginning 10/08/2025. On 10/08/2025 the reporting person had 4,483 RSUs treated as acquired upon vesting and sold 2,203 shares to satisfy tax withholding at a price of $16.85 per share. After these transactions the beneficial ownership reported is 8,967 ordinary shares. The Form 4 was signed by an attorney-in-fact on 10/09/2025.
Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN), received and settled restricted stock units in September 2025. On 09/07/2025 1,667 RSUs vested, each representing one ordinary share, increasing his beneficial ownership to 149,896 shares. On 09/08/2025 he sold 871 shares at $19.11 to satisfy withholding tax obligations, leaving him with 149,025 shares beneficially owned. The RSUs granted on 09/07/2023 totalled 5,000 and vest in three equal annual installments beginning 09/07/2024. The Form 4 was signed by an attorney-in-fact on 09/09/2025.
Insider transactions at UroGen Pharma Ltd. (URGN): Jason D. Smith, General Counsel, had 3,333 restricted stock units (RSUs) vest on 09/07/2025, which converted into 3,333 ordinary shares. On 09/08/2025 he sold 1,520 shares at $19.11 each to satisfy withholding tax obligations following the RSU settlement. After these transactions the reporting person beneficially owned 43,305 ordinary shares. The RSU grant referenced was originally for 10,000 shares, granted 09/07/2023 and vesting in three equal annual installments beginning 09/07/2024.